Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
| Sotyktu | deucravacitinib | Psoriasis, moderate to severe plaque | Do not reimburse | Complete | ||
| Sovaldi | Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Sovaldi | sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
| Spiriva Respimat | Tiotropium bromide | Chronic obstructive pulmonary disease | List with clinical criteria and/or conditions | Complete | ||
| Spravato | esketamine hydrochloride | Major depressive disorder (MDD), adults | Do not reimburse | Complete |
Last Updated : May 17, 2024